Aesthetic CRO Advantage DeNova Research specializes in aesthetic medicine, plastic surgery and dermatology, supported by a seasoned team and strong ethical standards. With on-site patient visits exceeding 6,500 annually and a research database of more than 7,500 subjects, they offer a robust enrollment and data pool for sponsors. This makes them an attractive partner for end-to-end trials, including protocol development, regulatory submissions, and rapid budgeting and contracting to accelerate study startup and execution.

Enrollment Excellence The company consistently achieves 119 percent of enrollment goals and sustains a 94 percent retention rate over the last three years, backed by a dedicated recruitment and retention specialist. This suggests a powerful enrollment engine and potential to enhance recruitment marketing, patient engagement platforms, and site optimization services to shorten timelines while preserving high retention.

Rapid Study Turnaround DeNova emphasizes timely protocol development, regulatory submissions and budget negotiations, enabling swift transitions from concept to execution. This aligns with sponsors seeking fast startup and reliable timelines, presenting an opportunity to offer integrated study management, regulatory affairs outsourcing, and streamlined eSubmissions workflows to boost speed and predictability.

Unique Subject Database The on-site clinical practice combined with a research database of more than 7,500 subjects and a dedicated recruitment stream provides sponsors with a rich data source and accessible pool for feasibility assessments and endpoint capture in dermatology and aesthetics trials. Opportunities include data analytics services, image-based endpoint capture support, and secure data-sharing arrangements to strengthen multi-study programs.

Growth Partnership Potential With a lean team (2 to 10 employees) and revenue in the sub-1 million range, DeNova presents a compelling case for scalable partnerships rather than standalone capacity. Targeted collaborations could involve flexible CRO services, co-developed pricing models, and regional expansion support to broaden trial access beyond Chicago and attract mid-market sponsors seeking niche aesthetic and dermatology expertise.